Rockwell Medical Technologies, Inc. to Present at JMP Securities Healthcare Focus Conference

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream.

Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy to these patients while decreasing drug administration cost.

About Soluble Ferric Pyrophosphate (SFP) - Rockwell's Lead Renal Drug Therapy Product

SFP is a water soluble form of iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP (iron) is uniquely delivered via dialysate directly to the bloodstream, during each kidney dialysis treatment. SFP is a highly stable, non-polymeric iron salt that is administered directly into the bloodstream, avoiding liver toxicity build-up thus overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell which facilitates transfer of iron from transferrin to ferritin, bypassing the liver entirely.

Based on an earlier FDA Phase II clinical study, SFP delivered via dialysate, was shown to be a safe and effective method for maintaining optimal iron balance in dialysis patients while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs.